Search - tctmd.com

Displaying 1 - 20 of 103

Sort: Relevancy | Date

Sirolimus DCB in Peripheral Disease Makes Strides in Hard Outcomes: SirPAD

News Conference News ACC 2026

Sirolimus DCB in Peripheral Disease Makes Strides in Hard Outcomes: SirPAD

April 02, 2026

Two Neutral IVUS Trials in Complex PCI—and One Positive—Spark Debate

News Conference News ACC 2026

Two Neutral IVUS Trials in Complex PCI—and One Positive—Spark Debate

April 02, 2026

Olezarsen Doesn’t Lower Plaque Volume: Essence-TIMI 73b

News Conference News ACC 2026

Olezarsen Doesn’t Lower Plaque Volume: Essence-TIMI 73b

Yael L. Maxwell

April 01, 2026

GoFreshRx, THRIVE Trials Show BP Benefits of ‘Food as Medicine’

News Conference News ACC 2026

GoFreshRx, THRIVE Trials Show BP Benefits of ‘Food as Medicine’

March 31, 2026

SMART-DECISION: Stopping Beta-blockers Post-MI Safe in Stable Patients

News Conference News ACC 2026

SMART-DECISION: Stopping Beta-blockers Post-MI Safe in Stable Patients

Michael O'Riordan

March 30, 2026

SPIRIT-HF: Spironolactone’s Benefit Still Uncertain in HF With Preserved, Mildly Reduced EF

News Conference News ACC 2026

SPIRIT-HF: Spironolactone’s Benefit Still Uncertain in HF With Preserved, Mildly Reduced EF

March 29, 2026

Noninvasive FFR Measures Match Wire-Based Assessment: ALL RISE and FAST III

News Conference News ACC 2026

Noninvasive FFR Measures Match Wire-Based Assessment: ALL RISE and FAST III

March 29, 2026

Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE

News Conference News ACC 2026

Very Low LDL Levels Best in Secondary Prevention: Ez-PAVE

Yael L. Maxwell

March 28, 2026

HI-PEITHO: Catheter-Directed Therapy Bests Anticoagulation in Intermediate-Risk PE

News Conference News ACC 2026

HI-PEITHO: Catheter-Directed Therapy Bests Anticoagulation in Intermediate-Risk PE

March 28, 2026

CHAMPION-AF: A Win for Watchman FLX, but With Caveats

News Conference News ACC 2026

CHAMPION-AF: A Win for Watchman FLX, but With Caveats

March 28, 2026

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

News Conference News ACC 2025

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

April 10, 2025

RACER: No Change in Cardiac Arrests During Marathons, but Survival Is Up

News Conference News ACC 2025

RACER: No Change in Cardiac Arrests During Marathons, but Survival Is Up

Michael O'Riordan

April 08, 2025

DETECT-AS: Alert System Increases AV Replacement in Eligible Patients

News Conference News ACC 2025

DETECT-AS: Alert System Increases AV Replacement in Eligible Patients

Michael O'Riordan

April 04, 2025

FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints

News Conference News ACC 2025

FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints

April 03, 2025

Nurses Can Be Pivotal in Post-ACS Secondary Prevention: ALLEPRE

News Conference News ACC 2025

Nurses Can Be Pivotal in Post-ACS Secondary Prevention: ALLEPRE

April 02, 2025

Tight Fluid Restriction Not Needed in Chronic HF Patients: FRESH-UP

News Conference News ACC 2025

Tight Fluid Restriction Not Needed in Chronic HF Patients: FRESH-UP

Michael O'Riordan

April 01, 2025

Shelf-stable Product May Sub in for Frozen Plasma in Cardiac Surgery: FARES-II

News Conference News ACC 2025

Shelf-stable Product May Sub in for Frozen Plasma in Cardiac Surgery: FARES-II

March 31, 2025

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

News Conference News ACC 2025

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

March 30, 2025

Strike Two: BHF PROTECT-TAVI Throws Cold Water on Embolic Protection

News Conference News ACC 2025

Strike Two: BHF PROTECT-TAVI Throws Cold Water on Embolic Protection

Michael O'Riordan

March 30, 2025

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

News Conference News ACC 2025

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

March 29, 2025

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.